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Abstract: Macrophages are important partici-
pants in neovascularization. This study was de-
signed to examine the role of the monocyte/
macrophage chemotactic proteins, monocyte che-
motactic protein-1 (MCP-1), and macrophage
inflammatory protein-1 (MIP-1) in a mouse
model of oxygen-induced ischemic retinopathy and
to determine whether the morphology and distri-
bution of macrophages/microglia are concomi-
tantly altered. The MCP-1, MIP-1 mRNA levels
increased at 3 h after ischemia. MCP-1, MIP-1,
and vascular endothelial growth factor protein lev-
els were also increased markedly and were maxi-
mal on days 1, 0.5, and 1, respectively, after isch-
emia. In situ hybridization showed that MCP-1 and
MIP-1 were localized in the hypoxic inner retina.
Immunostaining demonstrated that the macro-
phages/microglia in the retina had morphological
changes with enlarged processes, and some were
closely associated with neovascular tufts at post-
natal day 17. Coadministration of the neutraliz-
ing antibodies against MCP-1 and MIP-1 inhib-
ited retinal neovascularization by 30%. Our data
suggest that MCP-1 and MIP-1 are involved in
the induction of retinal neovascularization and
play a role in the inflammation induced by the
ischemic retinopathy, possibly by modulating or
attracting macrophages/microglia. J. Leukoc. Biol.
73: 137–144; 2003.
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INTRODUCTION
Intraocular neovascularization is a major cause of decreased
vision in patients with diseases such as proliferative diabetic
retinopathy (PDR), retinal vein occlusion, and retinopathy of
prematurity [1]. Although these diseases differ in many as-
pects, it is generally believed that the tissue ischemia common
to all of them initiates a series of events that leads to the
compensatory angiogenesis. Cellular inflammation is initiated
at the blood-microvascular endothelial-cell interface, and leu-
kocytic infiltration has been observed after focal ischemia in
central nervous system (CNS) lesions [2].
Among the inflammatory cells, macrophages carry out a wide
variety of biologic functions including participation in neovas-
cularization [3]. Macrophages are important among the key
angiogenic effector cells that produce a number of growth
stimulators and inhibitors, proteolytic enzymes, and cytokines
capable of modulating new vessel formation. Polverini et al. [4]
have demonstrated that conditioned media derived from acti-
vated macrophages can induce angiogenesis. In addition, tu-
mor-associated macrophage infiltration is correlated with tumor
angiogenesis in individuals with invasive breast cancer [5].
Macrophage infiltration also occurs in a number of retinal and
choroidal angiogenic diseases, such as PDR and age-related
macular degeneration [6]. However, it is not completely clear
how macrophages/microglia are involved in retinal angiogen-
esis.
Chemokines, a family of structurally related cytokines in-
volved in the activation and directed migration of immune
cells, may be pathophysiologically important mediators of in-
flammation [7]. Two well-studied CC chemokines are monocyte
chemotactic protein-1 (MCP-1) and macrophage inflammatory
protein-1 (MIP-1). MCP-1 mediates the recruitment of
monocytes [8] and can also induce corneal neovascularization
[9]. A strong induction of MCP-1 expression has been reported
following diverse CNS insults, including ischemic injury mod-
els [10, 11]. MCP-1 is also increased in the vitreous of patients
with PDR [12].
MIP-1, similar to MCP-1, has been shown to mediate the
recruitment of monocytes in several inflammatory diseases
[13]. A recent study has documented the importance of this
cytokine in mediating leukocytic infiltration and neovascular-
ization using a dermal wound pouch model [14]. We have also
demonstrated that MIP-1 is induced during inflammatory
neovascularization in the mouse cornea [15].
The angiogenic potential of cells and substances has been
determined in several angiogenic model systems, such as the in
vivo model of ischemia-induced retinal neovascularization [16,
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17]. Using this model, we previously demonstrated that the
transcription nuclear factor-B plays a significant role in reg-
ulating the expression of many genes, including chemokines
[18, 19]. However, it still remains unclear what roles the
chemotactic mediators play in ischemia-associated retinal neo-
vascularization.
Thus, we have investigated whether the monocyte/macro-
phage-attracting proteins MCP-1 and MIP-1 can be induced
in a mouse model of oxygen-induced ischemic retinopathy and
whether the morphology and distribution of macrophages/mi-
croglia are concomitantly altered. Additionally, we examined
the possible involvement of these chemokines in retinal neo-
vascularization.
MATERIALS AND METHODS
Murine model of oxygen-induced ischemic
retinopathy
All experimental procedures concerning animals were performed according to
the Association for Research in Vision and Ophthalmology Statement for the
Use of Animals in Ophthalmic and Vision Research.
A reproducible model of ischemia-induced retinal neovascularization has
been described in detail previously [19]. Briefly, litters of 7-day-old [postnatal
day 7 (P7)] C57BL/6 pups with their mothers were exposed to 75  2% oxygen
for 5 days and then returned to room air at age P12. The intraocular injections
were performed at P12 as described below. Pups of the same age that had been
kept in room air were used as controls. Mice were killed by an overdose of
intraperitoneal (i.p.) sodium pentobarbital.
Northern blot analysis
The cDNA for mouse MCP-1, MIP-1, vascular endothelial growth factor
(VEGF), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was con-
structed by reverse transcriptase-polymerase chain reaction (RT-PCR). The
primers were: for MCP-1, 5-ATCCCAATGAGTAGGCTGGAGAGC-3 and
5-CAGAAGTGCTTGAGGTGGTTGTG-3; for MIP-1, 5-ACCTGCTCAA-
CATCATGAAGG-3 and 5-AGATGGAGCTATGCAGGTGG-3; for VEGF,
5-TGTAACGATGAAGCCCTGGAG-3 and 5-TCACCGCCTTGGCTTGT-
CACA-3; and for GAPDH, 5-CCCACTAACATCAAATGGGG-3 and 5-
ATCCACAGTCTTCTGGGTGG-3. These sequences were derived from pub-
lished sequences [20–23].
The PCR conditions were 10 min at 94°C, followed by 35 cycles at 72°C for
20 s, 94°C for 30 s, and 60°C for 30 s, with a final extension step at 72°C for
5 min. The resulting PCR fragments were confirmed by direct dideoxynucle-
otide chain termination [24].
Retinas were removed at selected periods after ischemia, and total RNA was
extracted as described previously [25]. Eight retinas were pooled for each time
point, and experiments were repeated at least three times. The RNAs were
fractionated on a 1% agarose gel containing 2.2 M formaldehyde, transferred
onto a nylon membrane (Hybond N, Amersham, Buckinghamshire, UK), and
then cross-linked using UV radiation at 0.25 J/cm2 with FLUO-LINK (Viler
Lourmat, Marne-La-Vallée, Cedex, France). The membrane was hybridized to
32P-labeled DNA probes in a Hybrisol (Oncor, Inc., Gaithersburg, MD) at 42°C
for 24 h, washed twice at room temperature in 2x saline sodium citrate (SSC;
1xSSC0.15 M NaCl-0.015 M sodium citrate) and 0.1% sodium dodecyl
sulfate (SDS), once in 1x SSC and 0.1% SDS, and finally in 0.2x SSC and 0.1%
SDS. The mRNA levels were quantified by densitometry using a Scion Image
Beta 3b (Scion Corp., Frederick, MD), and signal intensities of various tran-
scripts were normalized by GAPDH mRNA level.
Real-time quantitative (q)RT-PCR
Real-time qRT-PCR was performed on the purified RNAs from retinas from
selected times. Total RNA was extracted from dissected mouse retinas, treated
with DNase, diluted by 20-fold in water, and subjected to reverse transcription
using standard procedures. PCRs were performed with the Roche LightCycler
system (Roche Molecular Biochemicals, Mannheim, Germany) with a SYBR-
Green Master kit (Roche Molecular Biochemicals). The primer pairs for MCP-1
and MIP-1 were the same as used in the Northern blot analysis described
above.
The optimal cycle programs were determined for each gene in preliminary
PCR runs to obtain a single, specific PCR product as verified by melting curve
analysis followed by gel electrophoresis. The cDNA quantities were calculated
with the LightCycler analysis software as described previously [26, 27]. MCP-1
and MIP-1 were normalized to hypoxanthine guanine phosphoribosyl trans-
ferase (HPRT; 5-CTACGAATCTCCGACCACCACTAC-3 and 5-GGCTTAT-
CATCTTTCAACACGCAG -3) cDNA fragments.
Enzyme-linked immunosorbent assay (ELISA)
Cytokine levels were measured using ELISA kits for MCP-1 (Biosource Inter-
national, Camarillo, CA), MIP-1, and VEGF (R&D Systems, Minneapolis,
MN), as described previously [28].
Retinas were removed from mice at 0, 0.5, 1, 2, 3, and 5 days after ischemia.
Each test sample was made up of four whole retinas. The retinas were
individually immersed in 500 l lysis buffer containing 20 mM imidazole HCl,
10 mM KCl, 1 mM MgCl2, 10 mM EGTA, 1% Triton, 10 mM NaF, 1 mM Na
molybdate, 1 mM EDTA (pH 6.8), supplemented with a protease inhibitor
cocktail (Roche Biomedical Systems, Indianapolis, IN), and were stored at
-80°C until use. When used, the samples were thawed, homogenized in
Polytron homogenizer (Kinematica AG, Lucerne, Switzerland), sonicated for
30 s, and clarified by centrifuging at 150 g for 10 min. The clarified retinal
lysates were then assayed using ELISA.
The total protein was determined with a commercial assay (Coomassie plus
protein assay reagent kit; Pierce, Rockford, IL) The sensitivities of the assays
for MCP-1, MIP-1, and VEGF were 9.0, 1.5, and 3.0 pg/ml, respectively.
Generation of riboprobes
The MCP-1 and MIP-1 cDNAs used for Northern blot analysis were sub-
cloned into TOPO-2 (Invitrogen, San Diego, CA) according to the manufac-
turer’s protocol. Their nucleotides were sequenced, and the inserts were
identified as murine MCP-1 and MIP-1. Clones with both orientations were
selected so that the same RNA polymerase (SP6) could be used to generate
antisense and sense riboprobes. The templates were linearized with EcoRV,
and in vitro transcription was performed using digoxigenin (DIG)-labeled
uridine triphosphate (Roche Biomedical Systems) according to the manufac-
turer’s protocol.
In situ hybridization
Mice retinas obtained 12 h after ischemia were fixed in 4% paraformaldehyde
for 2 h and embedded in paraffin. In situ hybridization was performed as
described in detail previously [15]. Briefly, retinas were rehydrated and treated
with proteinase K, followed by refixing in 4% paraformaldehyde in phosphate-
buffered saline (PBS) for 10 min. The retinas were then acetylated with 0.25%
acetic anhydride in 0.1 M triethanolamine-HCl buffer (pH 8.0) for 10 min,
dehydrated, and dried. Hybridization was performed with fresh hybridization
buffer [600 mM NaCl, 10 mM Tris-HCl (pH 7.6), 5 mM EDTA (pH 8.0),
1xDenhardt’s solution, 50% formamide, 17 mg/ml yeast tRNA, and 10%
weight/vol dextran] plus a sense or antisense DIG-labeled RNA probe for
12–16 h at 60°C. After hybridization, the retinas were washed to remove
nonspecifically bound RNA probe, and immunologic detection was performed
by anti-DIG Fab fragments conjugated to alkaline phosphatase as described in
the system protocol (Roche Biomedical Systems).
Immunohistochemistry of the retina
The eyes were enucleated, and the retinas were removed. They were fixed in
absolute ethanol at 4°C for 10 min, rehydrated in PBS for 15 min, and blocked
in normal serum for 30 min. The retinas were then incubated for 90 min at
37°C with rat monoclonal anti-F4/80 antibody (1:10 dilution; Biosource Inter-
national). After three washes with PBS, specimens were incubated with fluo-
rescein-conjugated goat anti-rat immunoglobulin G (IgG; Cappel, Durham, NC)
at room temperature for 3 h. Following three washes with PBS, specimens were
flat-mounted on microscope slides and examined under a Leica fluorescence
microscope (Wetzlar, Germany).
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Other eyes were fixed with 4% paraformaldehyde in PBS and embedded
in paraffin. Thin sections (3 m) were cut, and after removal of the paraffin,
they were rehydrated, blocked, and incubated for 1 h at room temperature
with anti-F4/80 antibody. Bound antibody was detected by a conventional
avidin-biotin-peroxidase protocol with 3-amino-9-ethylcarbazole as the
substrate. For negative controls, rat nonimmune IgG was used as the
primary antibody.
Intravitreal injections
Mice were deeply anesthetized by i.p. injections of sodium pentobarbital.
The lid fissure was opened, and the eyes were proptosed. Intravitreal
injections were performed on P12 and P14 by delivering 0.5 l (100 ng)
anti-MCP-1 antibody and anti-MIP-1 antibody (R & D Systems) to the left
eye and control preimmune antibody to the right eye with a 32-gauge
needle on a Hamilton syringe, 200 m posterior to the limbus. The eyes
were then repositioned, and the lids were approximated over the cornea.
For simultaneous administration of the anti-MCP and anti-MIP-1 anti-
body, premix of both antibodies was generated, and then 0.5 l (100 ng
each) was injected daily. Repeated injections were performed through a
previously noninjected area.
Quantification of neovascularization
The eyes of P17 mice were enucleated, fixed with 4% paraformaldehyde in
PBS, and embedded in paraffin. Serial 3-m-thick axial sections of the
retina were obtained starting at the optic nerve head. After staining with
hematoxylin and eosin, 10 intact sections of equal length, each 30 m
apart, were evaluated for a span of 300 m. All retinal vascular cell nuclei
anterior to the internal-limiting membrane were counted in each section
under a fully masked protocol. Averaging of all 10 counted sections yielded
the mean number of neovascular cell nuclei per 3-m section per eye. No
vascular cell nuclei anterior to the internal-limiting membrane were ob-
served in normoxic control animals.
Statistical analysis
Data were analyzed by one-way ANOVA followed by Bonferroni t-test. Results
are reported as the means  SEM.
RESULTS
Induction of MCP-1 and MIP-1 in the retinas of
mice with oxygen-induced ischemic retinopathy
MCP-1 and MIP-1 have recently been reported to play a
critical role in the pathogenesis of postischemic inflammation
in several ischemic injury models [2]. Therefore, we deter-
mined the mRNA levels of these inflammatory cytokines using
Northern blot analysis in mice with ischemic retinopathy (Fig.
1A). As it has already been reported that in the mouse model
of ischemic retinopathy, hyperoxia led to a significant down-
regulation of VEGF, and the subsequent hypoxia induced an
up-regulation of VEGF level [29–31], the level of VEGF
mRNA was determined as a positive control.
The expression of the mRNAs of MCP-1 and MIP-1 was
very low or undetectable in the retinas of the normal controls
and in P12 mice killed just 5 days after hyperoxia. A dramatic
increase in MCP-1 mRNA expression was observed 12 h after
the onset of hypoxia. The profile of MIP-1 mRNA expression
was similar to that of MCP-1 mRNA, except that a slight
increase of MIP-1 mRNA was detected in the retinas of mice
5 days (P12) after hyperoxia.
In contrast to MCP-1 and MIP-1, a steady level of VEGF
mRNA expression was found in the retinas of control, normal
mice. Hyperoxia resulted in a twofold decrease in the level of
VEGF mRNA, and the subsequent hypoxia led to a significant
up-regulation of VEGF expression by approximately fourfold
compared with that in the control retinas.
We also performed quantitative RT-PCR to examine the
level of chemokine gene expression at an earlier time point
(Fig. 1B). MCP-1 and MIP-1 mRNAs were slightly increased
in the retinas of mice 5 days (P12) after hyperoxia, and those
Fig. 1. (A) Northern blot determination of mRNA expression of MCP-1, MIP-1, and VEGF in mice with ischemic retinopathy. Representative blots of three
independent experiments are shown. Lane 1, Control retina (P12); lane 2, retina after 5 days exposure to hyperoxia (P12); lane 3, retina 12 h after ischemia (P12.5).
For control, the same blot was stripped and reprobed with GAPDH, and 18 S and 28 S ribosomal RNA were used for equal loading of RNA. Each lane contains
10 g total RNA. (B) Real-time, quantitative RT-PCR determining the mRNA levels of MCP-1 and MIP-1 at control P12, experimental P12, and 3 h after hypoxia.
All data were standardized by HPRT and divided by control value at P12. The bars show the mean  SEM of four independent experiments per time point. *,
Statistically significant differences (P0.01) compared with normal subjects.
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levels were dramatically enhanced by 180- to 100-fold, respec-
tively, as early as 3 h after ischemia.
ELISA was performed to determine the protein levels of
MCP-1, MIP-1, and VEGF. At 12 h after ischemia, the
MCP-1 protein level was markedly increased, peaked at 1 day
after ischemia (P13; 86.2 pg/mg total protein), and then de-
creased rapidly to return to undetectable levels by P17 (Fig.
2A). The MIP-1 protein levels were also markedly increased
at 12 h after ischemia (P12.5; 19.5 pg/mg total protein) and
then decreased more slowly than MCP-1 (Fig. 2B). The VEGF
protein levels similarly increased markedly after ischemia
(670.8 pg/mg total protein), reached a plateau between 12 h
and 1 day after ischemia, and showed a relatively gradual
decline compared with MCP-1 and MIP-1 (Fig. 2C).
The protein levels of MCP-1 and MIP-1 in the control
retinas and retinas of mice killed just after 5 days of hyperoxia
were below the level of detection (Fig. 2, A and B). Thus, we
could not apply any statistics to evaluate the significance of the
changes. In contrast, 50–70 pg/mg total protein of VEGF was
observed in the normal and hyperoxia-exposed retina (Fig. 2C).
Localization of MCP-1 and MIP-1 in the retinas
by in situ hybridization
To determine the cellular source of MCP-1 and MIP-1, serial
sections of retinal tissues obtained 	12 h after ischemia were
subjected to in situ hybridization with antisense or sense
riboprobes. In ischemic P12.5 retinas, MCP-1 was present
predominately in the hypoxic inner retina and most strongly, in
the retinal ganglion cell layer and in the cells located in the
inner nuclear layer (Fig. 3B), and cells located at both borders
of the inner nuclear layer showed distinct signals (Fig. 3B). In
situ hybridization with an antisense probe specific for MIP-1
showed a staining pattern similar to that seen with MCP-1 (Fig.
3E). Only a weak signal was seen in the negative controls
hybridized with sense probes (Fig. 3, C and F). The expression
of MCP-1 and MIP-1 with antisense riboprobes was very
weak, if any, in control P12.5 normal retinas (Fig. 3, A and D).
Morphology and location of F4/80-reactive
macrophage/microglia in normal and ischemic
retinas
These findings strongly suggest that MCP-1 and MIP-1 are
likely to be involved in the pathogenesis of ischemia-induced
retinopathy. We examined the morphology of macrophages/
Fig. 2. Kinetics of changes in protein levels of MCP-1 (A), MIP-1 (B), and
VEGF (C) in mice with ischemic retinopathy. Four retinas were measured at
the indicated times. Retinal lysates were prepared and were individually
assayed by ELISA. The bars show the mean  SEM of four independent
experiments per time point. *, Statistically significant differences (P0.01)
compared with normal subjects.
Fig. 3. In situ hybridization for MCP-1 and MIP-1 in the retinas of mice
with ischemic retinopathy. Hybridization was performed with antisense (A, B,
D, E) or sense (C, F) probes specific for MCP-1 (A–C) and MIP-1 (D–F). A,
D, Control normal retina (P12); B, C, E, and F, retina 12 h after ischemia
(P12.5). GCL, Ganglion cell layer; INL, inner-nuclear layer; ONL, outer-
nuclear layer. Original bar  50 m.
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microglia immunohistochemically to determine if they under-
went specific morphological changes following ischemic reti-
nopathy. Whole mounts of experimental and control mice ret-
inas were prepared, fixed in 4% formaldehyde, and stained
with F4/80 antibody. The whole mounts of the control retina
showed extensively ramified macrophages/microglia with slen-
der cell bodies (Fig. 4A). In contrast, microglial cells changed
from the resting, ramified morphology to a more distended
shape from approximately day 4 after ischemia (P16; Fig. 4B).
To localize these F4/80 cells, paraffin-embedded sections
were also prepared from P17 eyes. Cells positive to F4/80 were
found immediately adjacent to the neovascular tufts (Fig. 4C).
Nonimmune serum controls showed no staining (data not
shown).
Inhibition of retinal neovascularization by anti-
MCP-1 and anti-MIP-1 antibodies
To determine whether MCP-1 and MIP-1 were directly in-
volved in retinal neovascularization in this model, we next
examined whether neutralization of those chemokines would
attenuate the angiogenic response. The neovascularization was
assessed histologically by counting the number of endothelial
cell nuclei vitreal to the inner-limiting membrane. The retinas
of the control, antibody-treated eyes from the hypoxic mice
contained multiple neovascular tufts extending into the vitre-
ous, whereas retinas from control eyes of normoxic mice treated
with or without control antibody did not contain endothelial
cells at this location (Fig. 5).
Intravitreous injections of anti-MCP-1 or anti-MIP-1 anti-
bodies alone significantly affected the ischemia-induced reti-
nal neovascularization, although the degree of neovasculariza-
tion following each antibody was lower than in the control mice
(Fig. 6). However, when injected together, they inhibited the
neovascularization by 	30% (Fig. 6).
DISCUSSION
Our results demonstrated a dramatic increase of MCP-1 and
MIP-1 mRNA and proteins by Northern blot, qRT-PCR, and
ELISA, respectively, in response to ischemia in retinas of mice
(Figs. 1 and 2). In ischemic retinopathies, the inner retina,
which is supplied by retinal vessels, is hypoxic, whereas the
outer retina, which is supplied by the choroidal vessels, is not
[30]. In situ hybridization for MCP-1 and MIP-1 showed a
prominent increase of positive cells located in the inner retina
12 h after the ischemia (P12.5) in comparison to the lower level
of staining in the nonischemic retinas of control mice (Fig. 3).
Together, these results clearly demonstrated that in vivo isch-
emia enhances the expression of those leukocytic chemoattrac-
tants, and this ischemic, proinflammatory activation may con-
stitute a key event in initiating postischemic inflammation.
Additionally, simultaneous injection of anti-MCP-1 and
MIP-1 antibodies depressed the inflammatory neovascular-
ization (Figs. 5 and 6), indicating these molecules are indeed
involved in ischemia-induced retinal neovascularization. Re-
Fig. 4. Retinal macrophage/microglia visualized
using F4/80 immunohistochemistry in mice with
ischemic retinopathy. (A, B) Microglial changes
in the whole mount retina during retinal isch-
emia. In control P16 mice, retinal microglia dis-
play long, fine processes typical of resting micro-
glia (A). In P16 mice retina, the processes of
microglia are thicker, and the distended pro-
cesses are more evident (B). (C) Retinal sections
showing macrophages/microglia associated with
neovascular sprouts (arrow) in experimental P17 animals. Original bars  10 m (A) and 50 m (C).
Fig. 5. Retinal sagittal sections: the effect of antibod-
ies against MCP-1 and MIP-1 on oxygen-induced
retinopathy. Animals were subjected to 7 days of nor-
moxia, followed by 5 days of hyperoxia, and then by 5
days of normoxia. (A) Retinas of animals that received
only control antibody. Extensive preretinal neovascular
loops are apparent (arrows). (B) Retinas of animals that
received antibodies against MCP-1 and MIP-1. A
significant reduction in preretinal neovascular loops is
apparent compared with control antibody-treated eye.
(C) Retina of normal control animals exposed only to
room air. No preretinal neovascularization is seen.
Original bar  50 m.
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cently, a direct effect of MCP-1 on angiogenesis, which was not
related to its monocyte/macrophage recruitment, has been sug-
gested [32, 33]. This indicates that MCP-1 may have two
independent effects in this model: enhancement of the chemo-
taxis of monocytic cells and angiogeneic activity.
The inner retinal layer where ganglion cells and astrocytes
are located was the most prominent cellular site of MCP-1 and
MIP-1 gene expression in the hypoxic inner retina (Fig. 3, B
and D). This suggests that MCP-1 and MIP-1 expressed in
this region attract resident macrophages/microglia, vitreous
macrophages, and/or circulating monocytes through the blood:
retinal barrier toward the superficial layer of the retina where
neovascularization occurs. In support of this, macrophages
were observed in the vicinity of neovascular tufts at P17 (Fig.
4C) [34]. This observation further demonstrated the involve-
ment of MCP-1 and MIP-1 in the activation and/or recruit-
ment of macrophages/microglia by the ischemic retina. How-
ever, the extent to which MCP-1 and MIP-1 can coordinate
and/or differentially regulate the activation and recruitment of
macrophages/microglia still remains unknown. Further studies
are necessary to determine how the number and pattern of
distribution of the macrophages/microglia are altered by these
chemokines in the retinas of mice with ischemic retinopathy.
Only activated macrophages/microglia and granulocytes and
stimulated resident macrophages/microglia and granulocytes in-
duced angiogenesis after their implantation into the corneas in
several species [35]. Among the environmental stimuli, macro-
phage/microglia gene expression following ischemia is becoming
increasingly well-characterized to have angiogenic potential [36].
Macrophages/microglia in the ischemic retina exhibited thicker
and more distended processes compared with those in normal,
control retinas (Fig. 4B), and such “hypoxia-activated” macro-
phages have the potential to produce an array of angiogenic
cytokines and growth factors such as tumor necrosis factor-
(TNF-) and VEGF, which can contribute to the progression of
neovascularization. TNF- is an angiogenic molecule produced
by hypoxic macrophages [37, 38] and is a likely candidate for
angiogenic regulation [39]. It has been reported that TNF- level
is up-regulated in patients with PDR [40, 41], and we have
observed that the molecule is also expressed in the macrophages/
microglia in this model (S. Yoshida and A. Yoshida, unpublished
observation). TNF- released by activated macrophages may trig-
ger retinal neovascularization through induction of interleukin-8,
VEGF, or basic fibroblast growth factor in an autocrine or para-
crine manner [25, 42].
Another chemotactic factor of monocytes assayed in this
study was VEGF [43], which is a major mediator of retinal
ischemia-associated neovascularization [44]. Similar to MIP-
1, the expression of VEGF increased dramatically as early as
12 h after ischemia and declined relatively gradually toward
the prehypoxic level by P17 (Fig. 2C). VEGF might thus have
a dual effect on neovascularization in this model, enhancement
of the chemotaxis of monocytic cells, and angiogenesis activity.
A steady level of VEGF mRNA and protein was expressed in
the normal retina (Figs. 1 and 2). This is consistent with the
fact that VEGF is constitutively expressed in the adult retina
and is consistent with the role proposed for it in normal retinal
homeostasis and/or function [45, 46]. It has also been reported
that VEGF receptors are found outside the vasculature in
mouse neural retina [47], and abnormal expression of VEGF
may constitute a previously unknown risk factor for motor-
neuron degeneration [48]. These observations indicate that
manipulation of the VEGF pathway to inhibit pathologic neo-
vascularization would result in unexpected disturbances of
normal homeostasis in the retina and thus should be ap-
proached carefully [47]. In contrast, it is important to mention
that MCP-1 and MIP-1 are supposed to be nonfunctional in
normal retinas, in keeping with the very low levels of MCP-1
and MIP-1 in the normal control retinas (Figs. 1 and 2). This
raises the possibility that these chemokines might be an at-
tractive, therapeutic target to regulate “disease-specific” path-
ways in ischemia-induced retinopathy.
To the best of our knowledge, our study provides the first
evidence for the involvement of MCP-1 and MIP-1 and the
potential role of macrophage/microglia in the mouse model of
ischemic retinopathy. The results suggest that the postischemic
inflammation contributes to the pathogenesis of ischemia-in-
duced retinal neovascularization, possibly by modulating or
attracting inflammatory cells to the ischemic area. Thus, mod-
ulating the expression of MCP-1 and MIP-1 or the cognate
receptors and downstream signaling steps that activate quies-
cent macrophages/microglia as well as inhibiting microglial
secretion of angiogenic factors by ischemia could be a poten-
tial, novel, therapeutic strategy for inhibiting ischemia-associ-
ated retinal neovascularization.
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Fig. 6. Results of quantification of cell nuclei occurring on the vitreous side
of the internal-limiting membrane in sections from whole eyes of hyperoxia-
treated mouse pups. Antibodies to MCP-1 and MIP-1 alone did not signifi-
cantly inhibit ischemia-induced retinal neovascularization. In combination,
these antibodies reduced significantly the degree of oxygen-induced neovas-
cularization. *, P  0.05 versus control antibody. Data are shown as mean 
SEM.
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